Indigenous Covid-19 vaccine Covaxin has demonstrated interim clinical efficacy of 81 per cent in its phase three trial. The trial involved 25 thousand 800 participants across 21 sites.<br />''<br />''The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group resulting in vaccine efficacy of 81 per cent.<br />''<br />''The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research.<br />''<br />''Director-General of Indian Council of Medical Research, Dr. Balram Bhargava said that the journey of completely indigenous COVID-19 vaccine in less than eight months' time showcases the immense strength of Atmanirbhar Bharat. He said, it is also a testament to India's emergence as a global vaccine superpower.<br />''<br />''Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said that Covaxin demonstrated high clinical efficacy against Covid-19 and significant immunogenicity against the rapidly emerging variants. <br />